Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.
- Trial name
- NCT01790100
- Testing
- VX-135, Ribavirin
- Where
- Moldova
- Volunteers
- 20 people
- Sponsor
- Alios Biopharma Inc.
Hepatocellular Carcinoma, HCC
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
Approximately half of the patients receiving treatment for chronic hepatitis C virus (HCV) infection in the United States have advanced liver disease.
- Conditions
- Hepatocellular Carcinoma, HCC, Hepatitis C, HCV
- Trial name
- NCT02833298
- Testing
- Automated reminders, Patient navigation
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Respiratory Failure, Hepatitis C
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03625687
- Testing
- Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Hepatitis C
Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients
Patients are being asked to be part of this study because they are a liver transplant recipient and have the Hepatitis C Virus (HCV).
- Trial name
- NCT01592006
- Testing
- Peginterferon alfa-2a, Ribavirin, telaprevir
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Hepatitis C, Chronic
PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.
This 2-arm study was designed to evaluate the efficacy, safety, and tolerability of prophylactic PEGASYS plus COPEGUS after liver transplantation for hepatitis C, compared to initiation of antiviral therapy at the time of…
- Trial name
- NCT00087633
- Testing
- peginterferon alfa-2a [Pegasys], Copegus
- Where
- 28 sites in United States
- Volunteers
- 115 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Substance Use Disorders
Overcoming Psychiatric Barriers to the Treatment of Hepatitis C
The purpose of this study is to develop and evaluate a 9-month psychosocial intervention that will assist patients with hepatitis C in overcoming barriers that prevent them from becoming appropriate candidates for interferon…
- Conditions
- Hepatitis C, Substance Use Disorders, Mental Disorder
- Trial name
- NCT00407732
- Testing
- psychosocial intervention
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C
BreathID Multi-center HCV Liver Breath Test Study
The goal of this study is to validate the BreathID 13C-methacetin breath test (MBT) as a non-invasive simple-to-use metabolic test, which could be utilized to detect severe liver fibrosis (>2 in METAVIR) in patients with chronic…
- Trial name
- NCT00350714
- Testing
- MBT and BreathID
- Where
- 5 sites in United States, Israel
- Volunteers
- 75 people
- Sponsor
- Meridian Bioscience, Inc.
Hepatitis C
Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)
This is a single-dose, randomized, cross-sectional comparison study examining the relative safety and resulting blood level profiles after administration of a new boceprevir tablet formulation versus its current capsule…
- Trial name
- NCT01181804
- Testing
- boceprevir
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00591214
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C, Chronic
Telaprevir Open-Label Study in Co-Infected Patients
The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFN-alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated…
- Trial name
- NCT01500616
- Testing
- Telaprevir
- Where
- 29 sites in Belgium, Germany and 6 more
- Volunteers
- 122 people
- Sponsor
- Janssen-Cilag International NV
HIV, Hepatitis C
A Methadone Maintenance Treatment Outcome Study in Three Provinces in China
The primary goal of this PHE is to determine the effectiveness of a tailored education program for MMT service providers. It was to be evaluated through methadone dose levels prescribed to new patients after training completion.
- Conditions
- HIV, Hepatitis C, Syphilis, Herpes Simplex Type II
- Trial name
- NCT01315054
- Testing
- MMT provider dosage training, targeted counseling, national guidelines
- Where
- China
- Volunteers
- 4,258 people
- Sponsor
- Centers for Disease Control and Prevention
Hepatitis C
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C
Proof-of Concept, Open-Label, Two-Stage Study without Direct Individual Benefit The proposed study design consists of two treatment periods and one treatment arm.
- Trial name
- NCT01833845
- Testing
- Ribavirin, Hydroxychloroquine
- Where
- 2 sites in France
- Volunteers
- 4 people
- Sponsor
- BioLineRx, Ltd.
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Chronic Hepatitis C
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
This study aims to assess the role of ribavirin as an adjuvant to sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with previous treatment failure.
- Trial name
- NCT04695769
- Testing
- Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
- Where
- Egypt
- Volunteers
- 281 people
- Sponsor
- Helwan University
Hepatitis, Hepatitis C
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR [MK-5172]; 100mg), uprifosbuvir (UPR [MK-3682]; 450 mg) and ruzasvir (RZR [MK-8408]; 60 mg) with and without Ribavirin…
- Conditions
- Hepatitis, Hepatitis C, Digestive System Diseases, Flaviviridae Infections
- Trial name
- NCT02613403
- Testing
- MK-3682B, Ribavirin
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Natural History of Hepatitis C in Patients With Normal Liver Tests
The Major goals of this project was to assess the natural history of disease in chronic hepatitis C patients with normal ALT and to determine the virologic and host factors associated with disease severity.
- Trial name
- NCT00187473
- Testing
- liver biopsy
- Volunteers
- 92 people
- Sponsor
- University of California, San Francisco
Chronic HIV Infection
Hepatitis C in Prison: Study of Screening and Rapid Treatment (HEPAPRIS)
Due to the high prevalence of HCV in prison and the risk of transmission between inmates, the management of hepatitis C and its treatment must be optimal following the recommendations of AFEF.
- Trial name
- HEPAPRIS (NCT05649202)
- Testing
- Xpert® HCV Viral test, FibroScan® test
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C, Chronic
Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV
The purpose of the study was to assess in subjects with chronic hepatitis C (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the virologic response to 3 dose levels of Locteron™, dosed every 2 weeks, in…
- Trial name
- SELECT-2 (NCT00863239)
- Testing
- ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
- Where
- 24 sites in United States, Bulgaria and 2 more
- Volunteers
- 116 people
- Sponsor
- Biolex Therapeutics, Inc.
Hepatitis C Infection
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who…
- Trial name
- NCT02105701
- Testing
- Grazoprevir + Elbasvir, Ribavirin
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects
The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.
- Trial name
- NCT00926016
- Testing
- Pioglitazone (Actos)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Brooke Army Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.